Patent Law Weblog
recent posts
- Hikma Pharmaceuticals USA Inc. v. Amarin Pharma, Inc. (2026)
- Constellation Designs, LLC v. LG Electronics Inc. (Fed. Cir. 2026)
- Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc. (Fed. Cir. 2026)
- PTAB Reverses § 101 Rejection Where Examiner Failed to Follow the Office’s Own Guidance
- Collision Communications v. Samsung: What Good Did the Government’s Statement of Interest Do?
about
Month: August 2008
-
American Conference Institute (ACI) will be holding its 11th Advanced Forum on Structuring, Negotiating and Managing Pharma/Biotech Collaborative Agreements from November 12-14, 2008 in New York. The conference will allow attendees to: • Leverage intellectual property and draft favorable exclusivity provisions;• Anticipate the potential impact of M&A activity on your transaction;• Negotiate co-development rights;• Protect…
-
By Donald Zuhn — Regular Patent Docs readers have likely noticed that we have been paying close attention to the lobbying efforts of various players in the biotech/pharma industry. Our interest in the lobbying expenditures of these companies and organizations stems from the push by Congress over the past year to pass patent…
-
By Kevin E. Noonan — The Federal Circuit today affirmed AstraZeneca’s latest victory in its long-running battle against generic drug companies who filed ANDAs for its (former) blockbuster drug, Prilosec®. The Court affirmed in toto the decisions of Judge Barbara S. Jones, the District Court judge sitting in the Southern District of New…
-
By Donald Zuhn — The U.S. Patent and Trademark Office announced today that the latest version of the Manual of Patent Examining Procedure (M.P.E.P.) — 8th Edition, Revision 7 — is now available. The new version replaces Revision 6, which was released in October, 2007. The parts of the latest version of the…
-
By Kevin E. Noonan — The Supreme Court has spent the past few years issuing decision after decision circumscribing the Federal Circuit’s Congressionally-mandated authority over U.S. patent law, pursuant to its plenary powers under Article III of the Constitution. Among these decisions (including KSR Int’l Co. v. Teleflex Inc., eBay Inc. v. MercExchange,…
-
By Jason Derry — Tobira Therapeutics Inc. has announced that the U.S. Patent and Trademark Office has issued Patent No. 7,371,772. According to Tobira, the ‘772 patent, which is assigned on its face to Takeda Pharmaceutical Co. Ltd., covers a compound that Tobira currently has in Phase I development for the treatment of…
-
By Sherri Oslick — About Court Report: Each week we will report briefly on recently filed biotech and pharma cases, and a few interesting cases will be selected for periodic monitoring. Janssen Pharmaceutica N.V. et al. v. Sandoz, Inc.1:08-cv-00511; filed August 13, 2008 in the District Court of Delaware Infringement of U.S. Patent…
-
September 11, 2008 – Developments in Pharmaceutical and Biotech Patent Law (Practising Law Institute) – New York, NY September 11-12, 2008 – Current Issues in Complex IP Licensing (Law Seminars International) – Philadelphia, PA September 15-16, 2008 – Biotech Patents*** (American Conference Institute) September 21-23, 2008 – 2008 Annual Meeting (Intellectual Property Owners Association) –…
-
Patent Resources Group (PRG) will be holding its next group of Advanced Courses between October 15-21, 2008 in Santa Ana Pueblo, New Mexico. Among the courses being offered in October are: • Drafting Patent License Agreements – October 15-17• Hot Topics in Patent Law: Up-to-the-Minute Developments in the Courts, the Agencies & Congress – October…
-
By Donald Zuhn — Earlier this month, several European news outlets reported on a decision by the UK High Court of Justice declaring a Human Genome Sciences (HGS) patent disclosing the nucleotide and amino acid sequence of Neutrokine-alpha, a novel member of the TNF ligand superfamily, to be invalid. The High Court agreed…
Patent Docs 